CTI BioPharma Corp - Company Profile
Powered by 
All the data and insights you need on CTI BioPharma Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date CTI BioPharma Corp Strategy Report
- Understand CTI BioPharma Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on CTI BioPharma Corp patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| US20220241291A1 | Application | OXYGEN LINKED PYRIMIDINE DERIVATIVES | A61K31/519; A61K31/5377; C07D498/06; C07D498/08; C07D498/16; C07D498/18; C07D515/16; C07D515/18 | August 04, 2022 |
| EP3860655A4 | Search Report | VERFAHREN ZUR BEHANDLUNG VON FLT3-MUTIERTEM BLUTKREBS | A61K31/519; A61K31/529; A61K31/704; A61K31/706; A61K31/7068; A61K45/06; A61P35/02 | August 03, 2022 |
| WO2022056092A1 | Application | METHODS OF TREATING VIRAL INFECTION | A61K31/5377; C07D498/08; C12Y207/11001; Y02A50/30 | March 17, 2022 |
| BRPI0922736B1 | Grant | Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1(8,12)]heptacosa1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno, composição farmacêutica compreendendo este e uso deste | A61P35/00; C07B2200/13; C07C55/22; C07D201/10; C07D498/04; C07D498/08 | February 22, 2022 |
| IL289379A | Application | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt | A61P35/00; C07B2200/13; C07C55/22; C07D201/10; C07D498/04; C07D498/08 | February 01, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer